

## **PRESS RELEASE**

**The SOL Group signs a preliminary agreement for the acquisition of the Italian company Haemopharm Biofluids S.r.l. to strengthen its presence in the pharmaceutical field.**

The SOL Group - a multinational company operating in the technical, industrial, and medicinal gas sectors and in home care – announces the signing of a preliminary agreement aimed at the acquisition, through AIRSOL S.r.l., a wholly-owned subsidiary of SOL S.p.A., of the entire capital of the company Haemopharm Biofluids S.r.l., from the controlling company Bellco of the American Group Mozarc Medical. The completion of the transaction is expected in the first months of 2026.

Founded in 2002, Haemopharm Biofluids S.r.l. has been part of Medtronic/Mozarc Medical since 2016. The company develops and manufactures infusible pharmaceutical and dialysis solutions at its pharmaceutical plant in Tovo di Sant'Agata, in the province of Sondrio. For several years, it has partnered with Vivisol S.r.l., a SOL Group company specialised in home care, to produce fluids for peritoneal dialysis.

In the 2024 financial year, Haemopharm Biofluids S.r.l. recorded a turnover of approximately **8.1 million Euro**.

**Aldo Fumagalli Romario**, President and Chief Executive Officer of the SOL Group, commented: *"We are satisfied with this agreement which allows us to strengthen our presence in the pharmaceutical world; once the acquisition is completed, we will be able to develop innovative therapeutic proposals in the field of renal insufficiency, positioning ourselves increasingly as a point of reference for innovative services offered to the healthcare sector."*

**Claudio Garbellini**, General Director of SOL Group for the home care division, commented: *"We are glad to have the possibility to reinforce our position in the area of renal care in line with our mission of providing the best possible care for patients at home also in this sector"*.

**Ven Manda**, CEO of Mozarc, commented: *"I am pleased with the signing of this agreement for the sale of the Haemopharm Biofluids site to the SOL Group. This transaction represents a strategic evolution that allows Mozarc Medical to continue its exit from the adult acute and chronic dialysis businesses, focusing resources on our core programs while ensuring continuity for employees, patients, and customers."*

\*\*\*\*\*

SOL is an Italian multinational Group that operates in Europe, Turkey, Morocco, India, Brazil, China, Ecuador, Kuwait and Peru in two distinct prevalent sectors: the production, applied research, and marketing of technical, pure, and medicinal gases (Technical Gases Area) and home medical care (Home Care Area).

Contacts: Barabino & Partners  
Marina Riva  
Ph. +39 02 72 02 35 35  
m.riva@barabino.it

Monza, December 23<sup>rd</sup>, 2025